IRIS
PACINI, FURIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.223
EU - Europa 8.021
AS - Asia 3.705
SA - Sud America 664
Continente sconosciuto - Info sul continente non disponibili 200
AF - Africa 185
OC - Oceania 17
Totale 23.015
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.103
GB - Regno Unito 2.206
CN - Cina 1.351
RU - Federazione Russa 1.311
IT - Italia 1.242
SG - Singapore 1.131
IE - Irlanda 919
UA - Ucraina 562
BR - Brasile 530
SE - Svezia 507
VN - Vietnam 397
FR - Francia 395
DE - Germania 374
HK - Hong Kong 291
FI - Finlandia 224
KR - Corea 157
IN - India 101
ZA - Sudafrica 101
NL - Olanda 79
CA - Canada 58
BD - Bangladesh 56
AR - Argentina 49
TR - Turchia 47
ES - Italia 36
MX - Messico 31
PL - Polonia 30
BE - Belgio 29
IQ - Iraq 28
JP - Giappone 26
MA - Marocco 20
VE - Venezuela 18
NG - Nigeria 17
AT - Austria 16
EC - Ecuador 15
PK - Pakistan 15
CL - Cile 14
PY - Paraguay 14
AU - Australia 12
CZ - Repubblica Ceca 12
TN - Tunisia 11
UZ - Uzbekistan 11
ID - Indonesia 10
KE - Kenya 10
CH - Svizzera 9
CO - Colombia 9
SA - Arabia Saudita 9
BG - Bulgaria 8
EU - Europa 8
JO - Giordania 8
LT - Lituania 8
AL - Albania 7
CI - Costa d'Avorio 7
GR - Grecia 7
IL - Israele 7
IR - Iran 7
JM - Giamaica 7
OM - Oman 7
UY - Uruguay 7
HU - Ungheria 6
NP - Nepal 6
PT - Portogallo 6
RO - Romania 6
AE - Emirati Arabi Uniti 5
BO - Bolivia 5
DZ - Algeria 5
EG - Egitto 5
LB - Libano 5
NZ - Nuova Zelanda 5
PA - Panama 5
EE - Estonia 4
PH - Filippine 4
BY - Bielorussia 3
CR - Costa Rica 3
CY - Cipro 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GT - Guatemala 3
KZ - Kazakistan 3
MD - Moldavia 3
PE - Perù 3
SV - El Salvador 3
TH - Thailandia 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CU - Cuba 2
DK - Danimarca 2
ET - Etiopia 2
HN - Honduras 2
LV - Lettonia 2
MY - Malesia 2
PS - Palestinian Territory 2
RS - Serbia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BW - Botswana 1
GH - Ghana 1
IM - Isola di Man 1
Totale 22.811
Salva come PNG Salva come JPEG
Città #
Southend 2.031
Fairfield 1.241
Dublin 901
Dallas 859
Ashburn 793
Woodbridge 588
Chandler 581
Singapore 566
Santa Clara 478
Wilmington 468
Jacksonville 454
Seattle 453
Houston 440
Cambridge 399
Beijing 345
Moscow 326
San Jose 300
Milan 288
Ann Arbor 286
Hong Kong 277
Siena 275
Council Bluffs 197
The Dalles 181
Hefei 158
Seoul 154
Nanjing 153
Los Angeles 150
Princeton 147
Helsinki 112
Ho Chi Minh City 103
Lauterbourg 96
New York 91
Rome 89
Johannesburg 87
Boardman 86
Hanoi 85
San Diego 67
Munich 66
Dong Ket 56
Nanchang 55
Amsterdam 51
Buffalo 51
São Paulo 45
Florence 41
Saint Petersburg 40
San Mateo 40
London 39
Shanghai 39
Chicago 37
Düsseldorf 36
Columbus 32
Tianjin 31
Turku 30
Orem 29
Shenyang 29
Brussels 27
Kunming 27
Chennai 26
Jiaxing 26
Lancaster 26
Changsha 25
Figino 25
Guangzhou 25
Frankfurt am Main 24
Hebei 24
Phoenix 23
Washington 23
Izmir 21
Jinan 21
Brooklyn 20
Montreal 20
Prato 20
Dearborn 19
Tokyo 19
Zhengzhou 19
Norwalk 18
Redwood City 18
Abuja 17
Denver 17
Haiphong 17
Redondo Beach 17
Warsaw 17
San Francisco 16
Málaga 15
Ningbo 15
Belo Horizonte 14
Boston 13
Da Nang 13
Naples 13
Renton 13
Ankara 12
Biên Hòa 12
Brasília 12
Hangzhou 12
Manchester 12
Rio de Janeiro 12
Venezia 12
Atlanta 11
Bengaluru 11
Palermo 11
Totale 15.862
Salva come PNG Salva come JPEG
Nome #
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer 529
null 398
Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer 382
Alterations of the FSH and LH receptor genes and evaluation of sperm ultrastructure in men with idiopathic hypergonadotropic hypogonadism 350
DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients 345
Small papillary thyroid carcinoma with minimal extrathyroidal extension should be managed as ATA low-risk tumor 333
Obesity Does Not Modify the Risk of Differentiated Thyroid Cancer in a Cytological Series of Thyroid Nodules 327
Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group. 321
Reference range of serum calcitonin in pediatric population 307
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer 304
Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+ T lymphocytes 301
Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series but not in cytological series: evidence for selection bias 301
Approach to and treatment of differentiated thyroid carcinoma 299
Circulating miRNA95 and miRNA190 Are Sensitive Markers for the Differential Diagnosis of Thyroid Nodules in a Caucasian Population. 297
Weight loss associated with bariatric surgery does not restore short telomere length of severe obese patients after 1 year 297
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma 293
Acute exogenous TSH administration stimulates leptin secretion in vivo 282
Diagnostic Value of Circulating microRNA-95 and -190 in the Differential Diagnosis of Thyroid Nodules: A Validation Study in 1000 Consecutive Patients 273
Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients 266
Diagnostic, therapeutic and healthcare management protocols in parathyroid surgery: II Consensus Conference of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB) 261
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question 255
Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients 253
Management of thyroid nodules: a clinicopathological, evidence-based approach 249
MicroRNA expression profile of thyroid nodules in fine-needle aspiration cytology: a confirmatory series 249
Lack of Mutations of the Telomerase RNA Component in Familial Papillary Thyroid Cancer with Short Telomeres 244
Definition and management of radioactive iodine-refractory differentiated thyroid cancer 243
Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer 243
Mutations and polymorphism of LH and FSH receptors and sperm quality in men with hypergonadotropic hypogonadism without obvious testicular noxa 243
A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment 241
Short telomeres, telomerase reverse transcriptase gene amplification, and increased telomerase activity in the blood of familial papillary thyroid cancer patients 240
Changing natural history of differentiated thyroid cancer 238
Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer 234
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 233
Management of papillary thyroid microcarcinoma: primum non nocere! 230
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 228
Variants in MCT10 protein do not affect FT3 levels in athyreotic patients 228
Lack of germline A339V mutation in thyroid transcription factor-1 (TITF-1/NKX2.1) gene in familial papillary thyroid cancer. 227
Calcitonin Levels in Thyroid Disease Are Not Affected by Autoimmune Thyroiditis or Differentiated Thyroid Carcinoma 226
Clinical relevance of thyroglobulin doubling time in the management of patients with differentiated thyroid cancer 225
Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update 224
Validation of American Thyroid Association Ultrasound Risk-Adapted Approach for Repeating Cytology in Benign Thyroid Nodules 223
Telomere Abnormalities and Chromosome Fragility in Patients Affected by Familial Papillary Thyroid Cancer 221
Medullary thyroid carcinoma 220
Fine needle aspiration and medullary thyroid carcinoma: the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone 219
Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients 212
Ernest L. Mazzaferri, MD, MACP (1936-2013) 211
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 211
Serum Ghrelin As a Marker of Atrophic Body Gastritis in Patients With Parietal Cell Antibodies 209
IFNγ-Inducible Chemokines Decrease upon Selenomethionine Supplementation in Women with Euthyroid Autoimmune Thyroiditis: Comparison between Two Doses of Selenomethionine (80 or 160 μg) versus Placebo 207
Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cute-off level for RET/PTC rearrangements. 206
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 205
Reply to letter: Post-surgical thyroid ablation in intermediate risk-differentiated thyroid cancer patients 204
Molecular signature of indeterminate thyroid lesions: Current methods to improve fine needle aspiration cytology (FNAC) diagnosis 202
H. pylori (hp) infection and autoimmune diseases (ad): prevalence of infection in patients with Hashimoto's thyroiditis (ht) and allignement of thyroid hormones (th) with H. pylori proteins. 201
Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up 201
HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series 199
Best practice & research clinical endocrinology & metabolism. Thyroid nodules and cancer. Preface 198
Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients 198
Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? 198
Post-thyroidectomy chronic asthenia: self-deception or disease? 197
Management of differentiated thyroid cancer of the follicular epithelium 195
Multinodular goiter of unusual shape and location 194
Screening of thyroid nodules by serum calcitonin measurements: why not? 194
Genetic heterogeneity of HER2 amplification and telomere shortening in papillary thyroid carcinoma 192
Long-term efficacy of modified-release recombinant human thyrotropin augmented radioiodine therapy for benign multinodular goiter: results from a multicenter, international, randomized, placebo-controlled, dose-selection study 190
Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer 190
Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. 188
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer 186
Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis 184
Prevalence of parietal cell antibodies in a large cohort of patients with autoimmune thyroiditis 184
Observation for newly diagnosed micro-papillary thyroid cancer: is now the time? 183
Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions 181
Effects of Acute Recombinant Human TSH on Serum Ghrelin Levels 181
Telomeres and thyroid cancer 180
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial 179
Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology 179
A case of papillary thyroid cancer without aggressive histological features with nodal metastases detected during follow-up in a younger patients 179
Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal 175
Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. 174
Management of advanced medullary thyroid cancer 173
Response Letter to the Editor from Edmundo Avila-Hipolito: "Long-term effects of radioiodine in toxic multinodular goitre: thyroid volume, function and autoimmunity" 173
How Far Should We Go in the Search and Treatment of Recurrent or Persistent Lymph Node Metastases during Follow-Up of Thyroid Cancer Patients? 172
Extracellular superoxide dismutase induces mouse embryonic fibroblast proliferative burst, growth arrest, immortalization, and consequent in vivo tumorigenesis 172
Radioiodine therapy in the different stages of differentiated thyroid cancer 170
The low utility of pretherapy scans in thyroid cancer patients 169
The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels 169
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study 168
Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study 167
Targeted therapy in refractory thyroid cancer: current achievements and limitations 166
Rare diseases in clinical endocrinology: a taxonomic classification system 165
Bariatric Surgery Reduces Serum Anti-mullerian Hormone Levels in Obese Women With and Without Polycystic Ovarian Syndrome 164
New insight in the follow-up strategies of differentiated thyroid cancer 164
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium 163
Medullary thyroid cancer: management guidelines of the American Thyroid Association 158
Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand 157
Thyroid microcarcinoma 152
Manuale di medicina interna 151
The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carcinoma 148
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer 147
null 126
Totale 22.263
Salva come PNG Salva come JPEG
Categoria #
all - tutte 68.110
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 68.110
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.135 0 183 69 94 68 51 62 41 81 141 141 204
2022/20231.929 113 171 256 267 193 378 38 169 211 32 72 29
2023/20241.243 67 30 106 39 52 348 455 19 6 18 16 87
2024/20252.822 54 137 241 138 385 196 96 140 237 96 393 709
2025/20266.441 525 908 623 725 1.047 290 694 212 237 298 205 677
2026/2027475 278 197 0 0 0 0 0 0 0 0 0 0
Totale 23.015